Navigation Links
Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Melanoma Cancer Clinical Trial
Date:9/24/2009

CALGARY, Sept. 24 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY) announced today that the Cancer Therapy Research Center at the University of Texas Health Science Center (CTRC) has started patient enrolment in a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with metastatic melanoma. The Principal Investigator is Dr. Devalingam Mahalingam, M.D., Ph.D., MRCP(UK), MRCP(I), clinical investigator in GI/thoracic oncology and drug development at the CTRC.

"We have seen some very encouraging results in our clinical trials using REOLYSIN in combination with other therapies in metastatic melanoma patients," said Dr. Brad Thompson, President and CEO of Oncolytics. "For example, of nine evaluable melanoma patients treated intravenously in our combination REOLYSIN and chemotherapy trials, five had stable disease or better (two partial responses and three stable disease).

"In our local administration REOLYSIN and radiation studies, all of the evaluable melanoma patients (10) had stable disease or better in the target lesion, (three partial responses, one significant minor response and six stable disease). These results, combined with preclinical work demonstrating that in vivo combination treatment resulted in markedly reduced tumour growth compared to single agent treatments, provided the rationale for our collaborators to explore a Phase 2 combination study for patients with metastatic melanoma."

"Today, few effective treatment options exist for patients with advanced malignant melanoma," said Dr. Mahalingam. "We welcome this collaboration with Oncolytics, and are excited to have started patient enrolment for this Phase II investigator-initiated study at the CTRC. We are hopeful this no
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Oncolytics Biotech Inc. Announces Start of Patient Enrolment in Translational Clinical Trial Investigating REOLYSIN(R) in Patients with Metastatic Colorectal Cancer
2. Cancer Therapy & Research Center at The University of Texas Health Science Center and Oncolytics Biotech(R) Inc. Announce Multi-Trial Clinical Research Collaboration
3. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
4. Oncolytics Biotech(R) Inc. Announces Publication of Research on Synergistic Activity of Reovirus and Chemotherapy in NSCLC
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... LYON, France, Dec. 16 /PRNewswire/ -- ... the sanofi-aventis Group, announced today that it ... agreement with Syntiron to develop and commercialize ... including Methicillin-Resistant Staphylococcus aureus or ... infections in humans, sometimes referred to as ...
(Date:12/16/2009)... Lower Prescription Drug Prices ,, CHICAGO, Dec. ... night rejected an amendment to the Patient Protection ... prescription drugs more affordable by allowing for the ... from abroad. The bipartisan amendment, endorsed by ... Grassley and Stabenow, would have improved competition and ...
(Date:12/16/2009)... Ill., Dec. 16 Naurex Inc., a ... depression and other CNS disorders based on its ... it has initiated a Phase I clinical trial ... dosed the first subjects in the study. ... selective modulator of the NMDA receptor, is initially ...
Breaking Medicine Technology:Sanofi Pasteur Obtains License from Syntiron to Develop & Commercialize Vaccine to Prevent Staphylococcus Infections 2Sanofi Pasteur Obtains License from Syntiron to Develop & Commercialize Vaccine to Prevent Staphylococcus Infections 3Sanofi Pasteur Obtains License from Syntiron to Develop & Commercialize Vaccine to Prevent Staphylococcus Infections 4AARP Illinois Key Vote News Alert 2Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 2Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 3Former Connecticut Governor Lowell Weicker Jr Delivers Address on Health Reform 60458 1Former Connecticut Governor Lowell Weicker Jr Delivers Address on Health Reform 60458 2Former Connecticut Governor Lowell Weicker Jr Delivers Address on Health Reform 60458 3Women with chronic kidney disease more likely than men to go undiagnosed 60456 1Women with chronic kidney disease more likely than men to go undiagnosed 60456 2GE Healthcare President 26 CEO Mark Vachon to Present at BioConference Live 10595 1GE Healthcare President 26 CEO Mark Vachon to Present at BioConference Live 10595 2
(Date:12/16/2009)... DNA of a 1st century shrouded man found in a ... has revealed the earliest proven case of leprosy. Details of ... PloS ONE Journal. , The molecular investigation was undertaken ... the Sanford F. Kuvin Center for the Study of Infectious ... Carney Matheson and Ms. Kim Vernon of Lakehead University, Canada, ...
(Date:12/16/2009)... the families of sick and dying hospitalized children ask ... How do pediatricians respond to such personal requests? While ... help some patients and families cope with serious illness, ... the families and patients who raise the issue of ... issue of Southern Medical Journal , Brandeis and ...
(Date:12/16/2009)... million screenings conducted through national AAD program ... One person dies from melanoma, the deadliest form ... is often successfully treated, if caught early. That,s ... free skin cancer screenings in their communities through ... Cancer Screening Program. The program recently reached a ...
(Date:12/16/2009)... Medizone International, Inc. (OTC Bulletin Board: MZEI) ... the Board of Medizone New Zealand Ltd., a ... a 50% interest, agreed on December 14, 2009 ... Medizone International all global marketing rights of the ... G. Marshall said, "Time has eroded the relevance ...
(Date:12/16/2009)... to patient information could improve care, but privacy ... (HealthDay News) -- U.S. physicians support the use ... about privacy problems, two new studies show. , ... and specialist doctors in Massachusetts found that 86 ... improve patient quality of care, 70 percent thought ...
Breaking Medicine News(10 mins):Health News:DNA of Jesus-era shrouded man in Jerusalem reveals earliest case of leprosy 2Health News:DNA of Jesus-era shrouded man in Jerusalem reveals earliest case of leprosy 3Health News:Prayer on the hospital floor 2Health News:Dermatologists Reach Skin Cancer Screening Milestone 2Health News:Dermatologists Reach Skin Cancer Screening Milestone 3Health News:Medizone International, Inc. Approves Repurchase of Global Marketing Rights 2Health News:Pros and Cons of Electronic Medical Records Weighed 2
... CHAPEL HILL, N.C., April 16 Top Performers ... and,efficiency data -- when-possible and submit them for ... to raise awareness on key,humanistic and Quality of ... evidence based Guidelines and customize to managed care,organizations., ...
... Provide Revenue Cycle Solutions for ... Historic, 150 Year-Old Institution, PLANO, Texas, ... announced a new seven-year Revenue Cycle,Solutions agreement with New York ... Cycle Solutions that will,provide management and patient financial service professionals ...
... for aggressive breast cancer,Well-documented breast cancer tissue collection meets ... , Mammography and biopsies help find breast cancer, but ... will spread. Now, a two-year research project hopes to ... patients harboring not just breast cancer, but the nastiest ...
... Jenni Schaefer, a young,woman in Tennessee who ... to become a well-known motivational speaker, author, singer,songwriter ... been,appointed to the Ambassador Council of the National ... Schaefer will continue her travels nationally and,internationally, speaking ...
... According to New NCPA,Study, DALLAS, April 16 ... on low-income workers when they work,extra hours to get ... Center for Policy Analysis., "The impact on low-income ... Fellow Laurence Kotlikoff, Boston University,professor and author of the ...
... As potential cancer therapies proliferate, researchers and clinicians ... accurately predict which patients will receive the most benefit. ... Annual Meeting, April 12-16, 2008, researchers present data on ... doctors can more effectively measure response to commonly used ...
Other Medicine News:Health News:Perot Systems Selected to Implement Revenue Cycle Solution for New York Downtown Hospital 2Health News:Perot Systems Selected to Implement Revenue Cycle Solution for New York Downtown Hospital 3Health News:Research collaboration seeks blood test for aggressive breast cancer 2Health News:Research collaboration seeks blood test for aggressive breast cancer 3Health News:Jenni Schaefer, Motivational Speaker, Author Named National Eating Disorders Association (NEDA) Ambassador 2Health News:Tax Rates Mean Extra Work Doesn't Pay 2Health News:Measuring medicine: How new technologies could help doctors predict patient outcomes 2Health News:Measuring medicine: How new technologies could help doctors predict patient outcomes 3Health News:Measuring medicine: How new technologies could help doctors predict patient outcomes 4Health News:Measuring medicine: How new technologies could help doctors predict patient outcomes 5Health News:Measuring medicine: How new technologies could help doctors predict patient outcomes 6
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: